Media stories about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.7503090347474 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Aerie Pharma Moves HQ To NC, Preps for First Sales (ocbj.com)
- Stock’s Technical Analysis – Aerie Pharmaceuticals Inc (NASDAQ: AERI) – Alpha Beta Stock (alphabetastock.com)
- Brokerages Expect Aerie Pharmaceuticals Inc (AERI) Will Announce Earnings of -$0.89 Per Share (americanbankingnews.com)
- First in Class Drug for Glaucoma: What Pharmacists Need to Know (drugtopics.modernmedicine.com)
- Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference (finance.yahoo.com)
Several research analysts recently issued reports on the stock. Seaport Global Securities reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, March 5th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. HC Wainwright set a $78.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 1st. Cantor Fitzgerald set a $86.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Finally, Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $78.75.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($1.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.21) by ($0.17). sell-side analysts predict that Aerie Pharmaceuticals will post -3.62 EPS for the current fiscal year.
WARNING: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/03/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-aerie-pharmaceuticals-aeri-stock-price.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.